Innovaccer Inc., a leading healthcare AI company, today announced the launch of a comprehensive, AI-powered Readmissions Management Solution designed to help health systems and providers reduce avoidable readmissions, standardize transitional care management…
Minnesota Health Market Review 2025 Reveals Sharp Declines in HMO Profitability and Medicaid Enrollment It has released Part 1 of the “Minnesota Health Market Review 2025”, marking the 36th edition…
Paige, a leader in next-generation AI technology, today announced the release of PRISM2, its most advanced slide-level foundation model to date. PRISM2 is designed to advance large language models (LLM) by…
Netsmart and the Oregon Council for Behavioral Health (OCBH), a statewide nonprofit association dedicated to ensuring access to quality treatment and care, announced a new program aimed at enhancing behavioral health…
The leading provider of technology-enabled radiology services in the U.S., announced today the launch of its new technology services division, Mosaic Clinical Technologies™ and MosaicOS™ a proprietary, radiologist-driven platform designed…
Aviva Biopharm Reveals Promising Preclinical Results for d3-T, a First-in-Class Women’s Testosterone Therapy, at ENDO 2025 Aviva Biopharm Inc. (Aviva Bio), a clinical-stage biopharmaceutical company developing next-generation hormone therapies for…
A global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s…
BioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company addressingthe need for noninvasive, accurate tests for the detection of early-stage cancer, today released a new case study of a complex clinical…
A precision cardiovascular medicine company with a pioneering technology at the intersection of epigenetics and AI, today announced an agreement with AGEPHA Pharma that will enable the validation of a precision-guided approach…
A pioneer in cardiac treatment for microvascular disease, today announced that the U.S. Food & Drug Administration (FDA) has granted its technology an Investigational Use Exemption (IDE), allowing the pivotal…
Twist Bioscience Corporation, a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today accelerated its Express turnaround time for all Twist Gene…
A world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the company’s leadership position in the…